ReviewMolecules (Basel, Switzerland)2014
Relevance of the anti-inflammatory properties of curcumin in neurodegenerative diseases and depression.
Review in Molecules (Basel, Switzerland), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Potential therapeutic benefits of curcumin in depression or anxiety induced by chronic diseases: a systematic review of mechanistic and clinical evidence.Frontiers in pharmacology · 2025Pooled it
- Efficacy of curcumin in depression: A grade-assessed systematic review and meta-analysis of randomized controlled trials.Annals of general psychiatry · 2026Review
- Exploring the potential of polyphenols in major depression: from molecular function to clinical therapy.Frontiers in nutrition · 2026Review
- Role of manganese in brain health and disease: Focus on oxidative stress.Free radical biology & medicine · 2025Review
- A Spectrum of Solutions: Unveiling Non-Pharmacological Approaches to Manage Autism Spectrum Disorder.Medicina (Kaunas, Lithuania) · 2023Review
- Mancozeb-induced hepatotoxicity: protective role of curcumin in rat animal model.Toxicology research · 2023Article
- Relationship between Immune Cells, Depression, Stress, and Psoriasis: Could the Use of Natural Products Be Helpful?Molecules (Basel, Switzerland) · 2022Review
- Article
- PLGA-Based Curcumin Delivery System: An Interesting Therapeutic Approach in the Treatment of Alzheimer's Disease.Current neuropharmacology · 2022Review
- Curcumin-Piperlongumine Hybrids with a Multitarget Profile Elicit Neuroprotection in In Vitro Models of Oxidative Stress and Hyperphosphorylation.Antioxidants (Basel, Switzerland) · 2021Article
- Preparation and Characterization of Semi-IPN Cryogels Based on Polyacrylamide and Poly(Molecules (Basel, Switzerland) · 2021Article
- Therapeutic Potential of Curcumin as an Antimycobacterial Agent.Biomolecules · 2021Review
- Article
- Therapeutic and Mechanistic Effects of Curcumin in Huntington's Disease.Current neuropharmacology · 2021Review
- Nanoformulations of Herbal Extracts in Treatment of Neurodegenerative Disorders.Frontiers in bioengineering and biotechnology · 2020Review
- Novel Insight to Neuroprotective Potential of Curcumin: A Mechanistic Review of Possible Involvement of Mitochondrial Biogenesis and PI3/Akt/ GSK3 or PI3/Akt/CREB/BDNF Signaling Pathways.International journal of molecular and cellular medicine · 2020Review
- Curcumin as a therapeutic candidate for multiple sclerosis: Molecular mechanisms and targets.Journal of cellular physiology · 2019Review
- Formulations of Curcumin Nanoparticles for Brain Diseases.Biomolecules · 2019Review
- Protective Effects of Curcumin Against Ischemia-Reperfusion Injury in the Nervous System.Molecular neurobiology · 2019Review
- Curcumin Attenuates Asthmatic Airway Inflammation and Mucus Hypersecretion Involving a PPARMediators of inflammation · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
This review is an attempt to summarize our current understanding of curcumin's potential as a neuroprotectant and an antidepressant. This dual property confers a unique advantage to this herbal medication, believed to be devoid of any major side effects, to combat commonly observed co-morbid conditions of a neurodegenerative and a neuropsychiatric disorder. Moreover, in line with the theme of this series, the role of inflammation and stress in these diseases and possible anti-inflammatory effects of curcumin, as well as its interaction with signal transduction proteins as a common denominator in its varied mechanisms of action, are also discussed. Thus, following a brief introduction of curcumin's pharmacology, we present research suggesting how its anti-inflammatory properties have therapeutic potential in treating a devastating neurological disorder (Parkinson's disease = PD) and a debilitating neuropsychiatric disorder (major depressive disorder = MDD). It is concluded that curcumin, or better yet, an analog with better and longer bioavailability could be of important therapeutic potential in PD and/or major depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.